Broker Ratings

Danaher Corporation – Consensus ‘buy’ rating and 32.7% Upside Potential

Danaher Corporation which can be found using ticker (DHR) now have 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $310.00 and $240.00 calculating the average target price we see $268.26. Given that the stocks previous close was at $202.18 and the analysts are correct then we can expect a percentage increase in value of 32.7%. The day 50 moving average is $230.23 and the 200 day moving average is $251.69. The market capitalization for the company is 146.40B. The price for the stock stands currently at: $203.59 USD

The potential market cap would be $194,249,647,259 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 38.49, revenue per share of $32.29 and a 3.86% return on assets.

Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company’s segments include Biotechnology, which includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services; Life Sciences segment, which offers a range of instruments and consumables that are primarily used by customers to study the basic building blocks of life, including genes, proteins, metabolites, and cells, to understand the causes of disease, identify new therapies, and test and manufacture new drugs and vaccines; Diagnostics segment that offers clinical instruments, reagents, consumables, software, and services that hospitals, physicians’ offices, reference laboratories, and other critical care settings use to diagnose disease, and Environmental & Applied Solutions segment, which offers products and services that help protect precious resources and keep global food and water supplies safe.

Share on:
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

    Danaher Corporation (DHR) Stock Analysis: Strong Buy Ratings Signal Promising 14% Upside

    Danaher Corporation (NYSE: DHR) stands as a formidable entity in the healthcare sector, primarily operating within the diagnostics and research industry. With a commanding market capitalization of $157.52 billion, Danaher

    Danaher Corporation (DHR) Stock Analysis: Exploring a 16.5% Potential Upside for Investors

    Investors looking to diversify their portfolio with a strong player in the healthcare sector might find Danaher Corporation (NYSE: DHR) an intriguing option. Known for its extensive reach in diagnostics

    Danaher Corporation (DHR) Stock Analysis: Exploring a Potential 20% Upside Amidst Strong Buy Ratings

    Danaher Corporation (NYSE: DHR), a stalwart in the healthcare sector, stands as a compelling investment opportunity with a market capitalization of $144.97 billion. Specializing in the diagnostics and research industry,

    Danaher Corporation (DHR) Investor Outlook: Navigating a Robust 13.28% Potential Upside

    For investors seeking a strong foothold in the healthcare sector, Danaher Corporation (NYSE: DHR) presents a compelling opportunity with a significant potential upside. As a prominent player in the diagnostics

    Danaher Corporation (DHR) Stock Analysis: Unpacking a 31.76% Potential Upside

    As investors seek opportunities in the dynamic healthcare sector, Danaher Corporation (NYSE: DHR) presents a compelling case with a notable potential upside of 31.76%. With a substantial market capitalization of

    Danaher Corporation (DHR) Stock Analysis: Unlocking a 31.76% Potential Upside for Investors

    Danaher Corporation (NYSE: DHR), a heavyweight in the healthcare sector with a primary focus on diagnostics and research, offers a compelling opportunity for investors seeking growth in a robust industry.

      Search

      Search